自体造血干细胞移植治疗有自身免疫适应症的患者后感染并发症：一项系统回顾和荟萃分析方案

IF 2.2 4区医学 Q2 INFECTIOUS DISEASES

Infectious diseases now Pub Date : 2025-03-03 DOI:10.1016/j.idnow.2025.105050

Carolin-Sophie Wagner , Alexander Lithopoulos , Risa Shorr , Harold Atkins

{"title":"自体造血干细胞移植治疗有自身免疫适应症的患者后感染并发症：一项系统回顾和荟萃分析方案","authors":"Carolin-Sophie Wagner , Alexander Lithopoulos , Risa Shorr , Harold Atkins","doi":"10.1016/j.idnow.2025.105050","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>Autologous hematopoietic stem cell transplantation (aHSCT) offers potential long-term remission for various autoimmune diseases, especially in patients unresponsive to conventional treatments. Notwithstanding its benefits, aHSCT carries risks from cytotoxic agents and temporary immunosuppression, leading to infectious complications. This systematic review focuses on the incidence and characteristics of infections in patients with autoimmune diseases undergoing aHSCT.</div></div><div><h3>Patients and methods</h3><div>Data will be collected from trials identified in a search across Medline, Embase, Cochrane Register of Controlled Trials, Web of Science, <span><span>clinicaltrials.gov</span><svg><path></path></svg></span>, and the International Clinical Trials Registry Platform. Eligible publications are any articles that include patients undergoing autologous hematopoietic stem cell transplantation where the primary indication is an autoimmune disease. Outcomes include infection characteristics, treatment-related and all-cause mortality, and the robustness and quality of infection reporting. Data screening, collection, and extraction will be conducted using Covidence. A narrative synthesis will describe the results, and meta-analysis will be performed if possible.</div></div><div><h3>Results and conclusions</h3><div>This systematic review aims to define the risk of infections during and after stem cell transplantation for patients with autoimmune diseases with the goal of improving prophylaxis, early detection and treatment of infectious complications.</div></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"55 3","pages":"Article 105050"},"PeriodicalIF":2.2000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Infectious complications after autologous hematopoietic stem cell transplantation for patients with an autoimmune indication: A protocol for a systematic review and meta-analysis\",\"authors\":\"Carolin-Sophie Wagner , Alexander Lithopoulos , Risa Shorr , Harold Atkins\",\"doi\":\"10.1016/j.idnow.2025.105050\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><div>Autologous hematopoietic stem cell transplantation (aHSCT) offers potential long-term remission for various autoimmune diseases, especially in patients unresponsive to conventional treatments. Notwithstanding its benefits, aHSCT carries risks from cytotoxic agents and temporary immunosuppression, leading to infectious complications. This systematic review focuses on the incidence and characteristics of infections in patients with autoimmune diseases undergoing aHSCT.</div></div><div><h3>Patients and methods</h3><div>Data will be collected from trials identified in a search across Medline, Embase, Cochrane Register of Controlled Trials, Web of Science, <span><span>clinicaltrials.gov</span><svg><path></path></svg></span>, and the International Clinical Trials Registry Platform. Eligible publications are any articles that include patients undergoing autologous hematopoietic stem cell transplantation where the primary indication is an autoimmune disease. Outcomes include infection characteristics, treatment-related and all-cause mortality, and the robustness and quality of infection reporting. Data screening, collection, and extraction will be conducted using Covidence. A narrative synthesis will describe the results, and meta-analysis will be performed if possible.</div></div><div><h3>Results and conclusions</h3><div>This systematic review aims to define the risk of infections during and after stem cell transplantation for patients with autoimmune diseases with the goal of improving prophylaxis, early detection and treatment of infectious complications.</div></div>\",\"PeriodicalId\":13539,\"journal\":{\"name\":\"Infectious diseases now\",\"volume\":\"55 3\",\"pages\":\"Article 105050\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-03-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infectious diseases now\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666991925000296\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious diseases now","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666991925000296","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

目的自体造血干细胞移植（aHSCT）为各种自身免疫性疾病提供了潜在的长期缓解，特别是对常规治疗无反应的患者。尽管aHSCT有益处，但它也存在细胞毒性药物和暂时性免疫抑制的风险，从而导致感染性并发症。本系统综述的重点是自身免疫性疾病患者行aHSCT时感染的发生率和特征。患者和方法数据将从Medline、Embase、Cochrane对照试验注册、Web of Science、clinicaltrials.gov和国际临床试验注册平台上检索的试验中收集。符合条件的出版物是包括主要指征为自身免疫性疾病的患者接受自体造血干细胞移植的任何文章。结果包括感染特征、治疗相关死亡率和全因死亡率，以及感染报告的稳健性和质量。将使用covid - ence进行数据筛选、收集和提取。叙述性综合将描述结果，如果可能的话，将进行元分析。结果与结论本系统综述旨在明确自身免疫性疾病患者干细胞移植期间和移植后感染的风险，以改善感染并发症的预防、早期发现和治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Infectious complications after autologous hematopoietic stem cell transplantation for patients with an autoimmune indication: A protocol for a systematic review and meta-analysis

Objectives

Autologous hematopoietic stem cell transplantation (aHSCT) offers potential long-term remission for various autoimmune diseases, especially in patients unresponsive to conventional treatments. Notwithstanding its benefits, aHSCT carries risks from cytotoxic agents and temporary immunosuppression, leading to infectious complications. This systematic review focuses on the incidence and characteristics of infections in patients with autoimmune diseases undergoing aHSCT.

Patients and methods

Data will be collected from trials identified in a search across Medline, Embase, Cochrane Register of Controlled Trials, Web of Science, clinicaltrials.gov, and the International Clinical Trials Registry Platform. Eligible publications are any articles that include patients undergoing autologous hematopoietic stem cell transplantation where the primary indication is an autoimmune disease. Outcomes include infection characteristics, treatment-related and all-cause mortality, and the robustness and quality of infection reporting. Data screening, collection, and extraction will be conducted using Covidence. A narrative synthesis will describe the results, and meta-analysis will be performed if possible.

Results and conclusions

This systematic review aims to define the risk of infections during and after stem cell transplantation for patients with autoimmune diseases with the goal of improving prophylaxis, early detection and treatment of infectious complications.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊